Delhi HC issues interim order restraining Elder Projects from threatening Antex Pharma over ELDER, ELDERVIT trademarks use

Published On 2024-03-05 12:30 GMT   |   Update On 2024-03-06 06:27 GMT

In a significant legal development in New Delhi, the Delhi High Court issued an interim order restraining Mumbai-based Elder Projects from threatening Antex Pharma over the 'ELDER' and 'ELDERVIT' trademarks. Antex Pharma argued that their extensive use of these trademarks for pharmaceutical products has garnered significant goodwill, while Elder Projects allegedly made baseless legal threats...

Login or Register to read the full article

In a significant legal development in New Delhi, the Delhi High Court issued an interim order restraining Mumbai-based Elder Projects from threatening Antex Pharma over the 'ELDER' and 'ELDERVIT' trademarks. Antex Pharma argued that their extensive use of these trademarks for pharmaceutical products has garnered significant goodwill, while Elder Projects allegedly made baseless legal threats to assert rights over them. The court's decision reflects a cautious approach, balancing the protection of Antex Pharma from intimidation tactics with the recognition that ownership of the 'ELDER' trademark belongs to Elder Pharmaceuticals Ltd., as confirmed by a 2019 judgment. This ruling nullifies Elder Projects' claims. The interim order not only provides temporary relief to Antex Pharma but also signals the court's acknowledgment of the importance of fair competition and protecting established trademarks in the pharmaceutical industry. As the case progresses, it will have implications for trademark law and corporate practices in India's pharmaceutical sector, showcasing the judiciary's role in navigating trademark disputes.



Tags:    

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News